90-Minute Speed Read¶
A reader's path through the highest-value content in the corpus. Each item shows the time budget plus a one-line reason to read it. Stop markers at 10 / 35 / 60 / 75 / 90 minutes let you bail with what you've absorbed.
Read top-to-bottom. Each link opens the canonical page for that conference / trial / tool / talk.
0:00 — orient yourself (5 min)¶
| Item | Why read |
|---|---|
| Home | Quick skim of the 37-conference landscape — what's built vs scaffolded. |
| 2026 Timeline | Year-at-a-glance Gantt + 4-criterion scoring rubric for all 36 scored conferences. |
0:05 — the cancer-research anchor (5 min)¶
| Item | Why read |
|---|---|
| AACR 2026 — Overview | The anchor. Five axes (agentic AI, single-cell/spatial, virtual cells, bioinfo/AI methods, clinical trials) organize the rest of the corpus. |
🟢 Stop at 0:10 — you now know the corpus shape.
0:10 — what changed in cancer treatment this year (25 min)¶
ASCO GI (Jan 8–10, San Francisco) — 9 min:
| Trial | Why read |
|---|---|
| HERIZON-GEA-01 | Zani+chemo displaces 1L HER2+ G/GEJ; the PD-L1 CPS≥1 line is the IO-benefit threshold. |
| BREAKWATER cohort 3 | Enco+cetux+FOLFIRI gives BRAF mCRC ~30 vs 15 mo OS — new 1L SOC. |
| Daraxonrasib + zoldonrasib PDAC | The RAS(ON) wave hits the clinic; ctDNA dynamics are the early-readout biomarker. |
ASCO GU (Feb 26–28, San Francisco) — 9 min:
| Trial | Why read |
|---|---|
| KEYNOTE-B15 / EV-304 | EV+pembro displaces cisplatin in MIBC — EFS HR 0.53. |
| LITESPARK-022 | First adjuvant ccRCC trial to layer a mechanism on already-active pembro; raises the additive-benefit bar. |
| PEACE-3 | Ra-223 rehabilitated as combo with enza in mCRPC; mid-trial bone-protection amendment was the pivot. |
SGO (Apr 10–13, San Juan) — 7 min:
| Trial | Why read |
|---|---|
| ROSELLA | First GR-antagonist Phase 3 solid-tumor win; relacorilant+nab-pac for platinum-resistant ovarian. |
| RUBY 4-yr OS | Dostarlimab+chemo dMMR endometrial — 73% 4-yr OS plateau. |
🟢 Stop at 0:35 — you have the 2026 cancer-clinical pulse.
0:35 — bioinformatics tools (25 min)¶
EuroBioC 2025 (Sep, Barcelona) — 14 min:
| Item | Why read |
|---|---|
| Themes & takeaways | Spatial-omics convergence + cross-language interop as the year's two big patterns. |
| DESpace | Reframes SVG/DSP as a familiar NB-GLM problem on cluster covariates. |
| SpatialData | The Zarr/OME-NGFF cross-language framework that bridges Python scverse to R/Bioc. |
| iSEE | The canonical interactive viz citizen — S4 panel graph + code-extraction. |
GBCC 2025 (Jun, Cold Spring Harbor) — 11 min:
| Item | Why read |
|---|---|
| Themes & takeaways | The "joint" Galaxy+Bioc rationale and the agentic-AI-augmented-analysis inflection. |
| plyxp | dplyr for SummarizedExperiment — Mike Love's bridge from S4 to tidyverse. |
| bioc-to-galaxy | LLM-assisted DESCRIPTION → Galaxy-XML translator; the load-bearing meta-story of GBCC. |
🟢 Stop at 1:00 — you know the 2025 bioinformatics-tools landscape.
1:00 — AI/ML inflections in biology (15 min)¶
ICLR 2026 (Apr 23–27, Rio) — 9 min:
| Tool | Why read |
|---|---|
| MedAgentGym | 72k-task sandboxed code-exec gym + Med-Copilot-7B; primary AACR agentic-AI anchor. |
| Proteina Complexa | Atomistic protein binder design; 63.5% PDGFR hit rate, first de novo carbohydrate binders. |
| sc-Arena | Knowledge-augmented virtual-cell benchmark — answers "how do you actually score a virtual cell?". |
ISBI 2026 (Apr 8–11, London) — 6 min:
| Item | Why read |
|---|---|
| Mahmood pathology FM keynote | Three-tier FM stack (DINOv2 encoder + attention-MIL + task heads) scaling to >100M H&E tiles. |
| Segmentation FMs synthesis | The SAM-3 / MedSAM / SegVol line — promptable medical FMs with native-3D extensions. |
🟢 Stop at 1:15 — you have the 2026 AI/ML-in-biology map.
1:15 — brain cancer deep cut (10 min)¶
AACR Brain Tumors 2026 (Mar 23–25, Philadelphia):
| Talk | Why read |
|---|---|
| Monje GD2 CAR-T DIPG | Strongest pediatric CNS CAR-T signal to date — H3K27M-locked OPC-like DMG. |
| Suva glioma cell states | The AC/MES/OPC/NPC four-state framework that dictates CAR-T antigen-escape geography. |
| Neuroscience of gliomas + TAM (synthesis) | Neuron-glioma AMPAR synapses + TREM2/SPP1 TAM convergence — the year's most coherent CNS story. |
🟢 Stop at 1:25 — you've gone deep on one disease.
1:25 — sequencing platforms (5 min)¶
AGBT 2026 (Feb 22–25, Marco Island):
| Launch | Why read |
|---|---|
| Roche Axelios 1 | $150 / 30× duplex genome anchor; Roche's nanopore SBX comeback resets the cost-per-genome conversation. |
🟢 Stop at 1:30 — full speed-read complete.
If you have more time¶
Stretch picks for a 2-hour follow-on:
- JPM 2026 themes — the year's financial/strategic frame
- Element VITARI + Ultima UG200 — the $100 genome floor
- ACMG Presidential Plenary — NBS expansion — newborn genomic screening at population scale
- PSMAaddition — Lu-PSMA-617 moves three lines earlier into 1L mHSPC
- sc-FM Perturbation Adapter — <1% drug-conditional adapter for zero-shot perturbation prediction
- DeeDeeExperiment + Tidyomics — the data-class evolution for Bioconductor
Or pivot to a scaffolded vault to track an upcoming meeting:
- May 26–29: RECOMB 2026 — methods/algorithms
- May 29–Jun 2: ASCO 2026 — biggest oncology readout of the year
- Jun 11–14: EHA 2026 — European hematology
- Jun 13–16: ESHG 2026 — European human genetics (same week as EHA)
How this was curated¶
The speed-read picks favor (1) practice-changing or class-defining results, (2) tools likely to recur across multiple 2026 vaults, and (3) the cross-vault stories (cancer-clinical pulse, bioinformatics-tools evolution, AI/ML-in-biology inflection). Each section is sized to land at a natural stopping point so you can quit early without losing the through-line.
Comprehensive coverage lives in the conference vaults themselves — this page is the optimized path for someone who has 90 minutes and wants the highest-value cross-section.